Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis Mauriac

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Clinical Breast Cancer|October 28, 2004
Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trialDavid Miles, Svetislava Vukelja, Vladimir Moiseyenko, et al.
Anticancer Research|August 19, 2007
Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trialMichele Tubiana-Hulin, Veronique Becette, Ivan Bieche, et al.
Radiology|June 14, 2012
Radiofrequency ablation as a substitute for surgery in elderly patients with nonresected breast cancer: pilot study with long-term outcomesJean Palussière, Corinne Henriques, Louis Mauriac, et al.
Springerplus|September 26, 2015
Comprehensive prognostic analysis in breast cancer integrating clinical, tumoral, micro-environmental and immunohistochemical criteriaIsabelle de Mascarel, Marc Debled, Véronique Brouste, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancerMaïa Chanrion, Vincent Negre, Hélène Fontaine, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2015
Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitudeMarc Debled, Gaëtan MacGrogan, Christelle Breton-Callu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2008
Epithelial atypia: a marker risk of concomitant or subsequent breast carcinoma?Isabelle de Mascarel, Gaëtan MacGrogan, Anne Vincent-Salomon, et al.
Cancer|June 7, 2005
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trialsAnthony Howell, John Pippen, Richard M Elledge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Time for reappraisal of progesterone-receptor testing in breast cancer managementGaëtan MacGrogan, Isabelle de Mascarel, Ghyslaine Sierankowski, et al.
Annals of Surgical Oncology|November 26, 2010
Ductal carcinoma in situ of the breast: influence of age on diagnostic, therapeutic, and prognostic features. Retrospective study of 812 patientsChristine Tunon-de-Lara, Gwenaëlle André, Gaétan Macgrogan, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Clinical Breast Cancer|October 28, 2004
Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trialDavid Miles, Svetislava Vukelja, Vladimir Moiseyenko, et al.
Anticancer Research|August 19, 2007
Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trialMichele Tubiana-Hulin, Veronique Becette, Ivan Bieche, et al.
Radiology|June 14, 2012
Radiofrequency ablation as a substitute for surgery in elderly patients with nonresected breast cancer: pilot study with long-term outcomesJean Palussière, Corinne Henriques, Louis Mauriac, et al.
Springerplus|September 26, 2015
Comprehensive prognostic analysis in breast cancer integrating clinical, tumoral, micro-environmental and immunohistochemical criteriaIsabelle de Mascarel, Marc Debled, Véronique Brouste, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancerMaïa Chanrion, Vincent Negre, Hélène Fontaine, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2015
Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitudeMarc Debled, Gaëtan MacGrogan, Christelle Breton-Callu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2008
Epithelial atypia: a marker risk of concomitant or subsequent breast carcinoma?Isabelle de Mascarel, Gaëtan MacGrogan, Anne Vincent-Salomon, et al.
Cancer|June 7, 2005
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trialsAnthony Howell, John Pippen, Richard M Elledge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Time for reappraisal of progesterone-receptor testing in breast cancer managementGaëtan MacGrogan, Isabelle de Mascarel, Ghyslaine Sierankowski, et al.
Annals of Surgical Oncology|November 26, 2010
Ductal carcinoma in situ of the breast: influence of age on diagnostic, therapeutic, and prognostic features. Retrospective study of 812 patientsChristine Tunon-de-Lara, Gwenaëlle André, Gaétan Macgrogan, et al.
Pageof 6